Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
54.37
+4.56 (+9.15%)
Streaming Delayed Price
Updated: 11:00 AM EST, Jan 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
January 20, 2026
Via
ACCESS Newswire
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Via
ACCESS Newswire
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
January 05, 2026
Via
ACCESS Newswire
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
December 18, 2025
Via
ACCESS Newswire
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Via
ACCESS Newswire
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
December 15, 2025
Via
ACCESS Newswire
Global AI Infrastructure Shift Ignites Biotech Growth Phase
December 09, 2025
From
USA News Group
Via
GlobeNewswire
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
November 20, 2025
Via
ACCESS Newswire
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
November 20, 2025
Via
ACCESS Newswire
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
November 19, 2025
Via
ACCESS Newswire
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
November 18, 2025
Via
ACCESS Newswire
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
Via
ACCESS Newswire
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
November 03, 2025
Via
ACCESS Newswire
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
October 23, 2025
Via
ACCESS Newswire
Moderna to Host Investor Event - Analyst Day
October 23, 2025
Via
ACCESS Newswire
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
October 22, 2025
Via
ACCESS Newswire
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
October 19, 2025
Via
ACCESS Newswire
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
October 16, 2025
Via
ACCESS Newswire
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
October 12, 2025
Via
ACCESS Newswire
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
September 24, 2025
Via
ACCESS Newswire
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
September 23, 2025
Via
ACCESS Newswire
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
September 19, 2025
Via
ACCESS Newswire
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
September 16, 2025
Via
ACCESS Newswire
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
September 02, 2025
Via
ACCESS Newswire
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
August 27, 2025
Via
ACCESS Newswire
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
August 22, 2025
Via
ACCESS Newswire
Moderna to Present at Upcoming Conferences in September 2025
August 21, 2025
Via
ACCESS Newswire
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 01, 2025
Via
ACCESS Newswire
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
August 01, 2025
Via
ACCESS Newswire
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
July 30, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
